Avalo Therapeutics(AVTX) - 2023 Q4 - Annual Results

Exhibit 99.1 Avalo Reports 2023 Financial Results and Provides Business Updates • Acquired AVTX-009, Phase-2 ready anti-IL-1β mAb, in March 2024 • Increased cash position with private placement financing in March 2024 providing up to $185 million, including initial upfront investment of $115.6 million • Topline results from planned Phase 2 trial of AVTX-009 in hidradenitis suppurativa expected in 2026 • Expected cash runway into 2027 WAYNE, PA AND ROCKVILLE, MD, March 29, 2024 — Avalo Therapeutics, Inc. (Na ...